Q2-osavuosiraportti
82 päivää sitten‧12 min
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 31.3. | |
| 2024 Vuosiraportti | 31.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
20.9.·This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.com https://aspargolabs.com- 16.9.·📈 Technical and fundamental signals in focus The stock shows positive technical signs on the monthly chart: ✅ OBV breaks up – volume precedes price ✅ MACD turns up ✅ PVO strengthens momentum OBV may be a sign that institutional investors have started to position themselves. This may indicate that “smart money” expects a larger move ahead. The price has consolidated – but behind the scenes, things are happening. OBV is based on the principle that “volume precedes price”. This means that volume changes often occur before the price movement itself picks up. Bullish divergence: When the stock price makes lower lows but OBV shows higher lows, it indicates that sellers are losing power – a potential signal that an upward turn is near. Volume spikes: If OBV breaks past resistance while the price is still moving sideways, it may indicate that the price is about to make a breakthrough and may soon start following the upward move. ⸻ 🔬 Fundamental catalysts to watch: • Ovaprene study may be completed before June 2026 (according to new update in September on ClinicalTrials.gov). Potential game-changer in women's health. • Sildenafil for women could generate significant revenue as early as 2026 – difficult to quantify, but the upside is there. Sales are planned to begin in Q4, 2025. • Capital raising recently completed: 4.3M shares sold for $18M. The price was pressured in the short term – but the company is now funded for a year. The subsequent decline in the share price seems mainly linked to this dilution, rather than fundamental deterioration – something that came after the positive Ovaprene news this summer. • In Q4 we will learn which funds bought in at an average of $4.16 – can provide strong signaling value. ⸻ 📊 OBV – why it matters: When OBV breaks up while the price is still – it is often the price that adjusts. Volume = early warning. Bullish divergences + rising volume = momentum is building. The price can be still for months – but when it breaks free, it can move quickly. ⸻ 💡 Summary: The risk level is high – but so is the potential. The combination of certain technical indicators in the monthly chart, potentially new stronger owners and possible catalysts gives reason to keep the stock under surveillance for 2026. The stock's shorting has dropped sharply to about 200k from 1.1M since this summer, but shorts are still active, which is noticeable in that short borrow fee rates are around 10%. The technicals are constructive, especially on the monthly chart, while fundamentals such as the Ovaprene study, potential Sildenafil revenue and potential increased institutional ownership support a more positive long-term view. The short term may remain sluggish, but indicators point to a possible breakout as volume and sentiment converge. My assessment is that the “smart money” has already started to position itself, suggesting that a larger move may be in the offing. If so, there is potential for the price to once again reach levels seen at the peaks of the past five years. For those who are familiar with the company, it becomes clear that there are several potential catalysts ahead. Several analysts’ target prices have recently been updated to an average of $10.33, with a buy recommendation. Today, the stock is trading at $2. My opinion and no advice. I have recently purchased shares. Read up on the company, especially their SEC filings. https://ir.darebioscience.com/financial-information/sec-
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
82 päivää sitten‧12 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 20.9.·This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.com https://aspargolabs.com
- 16.9.·📈 Technical and fundamental signals in focus The stock shows positive technical signs on the monthly chart: ✅ OBV breaks up – volume precedes price ✅ MACD turns up ✅ PVO strengthens momentum OBV may be a sign that institutional investors have started to position themselves. This may indicate that “smart money” expects a larger move ahead. The price has consolidated – but behind the scenes, things are happening. OBV is based on the principle that “volume precedes price”. This means that volume changes often occur before the price movement itself picks up. Bullish divergence: When the stock price makes lower lows but OBV shows higher lows, it indicates that sellers are losing power – a potential signal that an upward turn is near. Volume spikes: If OBV breaks past resistance while the price is still moving sideways, it may indicate that the price is about to make a breakthrough and may soon start following the upward move. ⸻ 🔬 Fundamental catalysts to watch: • Ovaprene study may be completed before June 2026 (according to new update in September on ClinicalTrials.gov). Potential game-changer in women's health. • Sildenafil for women could generate significant revenue as early as 2026 – difficult to quantify, but the upside is there. Sales are planned to begin in Q4, 2025. • Capital raising recently completed: 4.3M shares sold for $18M. The price was pressured in the short term – but the company is now funded for a year. The subsequent decline in the share price seems mainly linked to this dilution, rather than fundamental deterioration – something that came after the positive Ovaprene news this summer. • In Q4 we will learn which funds bought in at an average of $4.16 – can provide strong signaling value. ⸻ 📊 OBV – why it matters: When OBV breaks up while the price is still – it is often the price that adjusts. Volume = early warning. Bullish divergences + rising volume = momentum is building. The price can be still for months – but when it breaks free, it can move quickly. ⸻ 💡 Summary: The risk level is high – but so is the potential. The combination of certain technical indicators in the monthly chart, potentially new stronger owners and possible catalysts gives reason to keep the stock under surveillance for 2026. The stock's shorting has dropped sharply to about 200k from 1.1M since this summer, but shorts are still active, which is noticeable in that short borrow fee rates are around 10%. The technicals are constructive, especially on the monthly chart, while fundamentals such as the Ovaprene study, potential Sildenafil revenue and potential increased institutional ownership support a more positive long-term view. The short term may remain sluggish, but indicators point to a possible breakout as volume and sentiment converge. My assessment is that the “smart money” has already started to position itself, suggesting that a larger move may be in the offing. If so, there is potential for the price to once again reach levels seen at the peaks of the past five years. For those who are familiar with the company, it becomes clear that there are several potential catalysts ahead. Several analysts’ target prices have recently been updated to an average of $10.33, with a buy recommendation. Today, the stock is trading at $2. My opinion and no advice. I have recently purchased shares. Read up on the company, especially their SEC filings. https://ir.darebioscience.com/financial-information/sec-
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 31.3. | |
| 2024 Vuosiraportti | 31.3. |
Datan lähde: Morningstar, Quartr
Q2-osavuosiraportti
82 päivää sitten‧12 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 31.3. | |
| 2024 Vuosiraportti | 31.3. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 20.9.·This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.com https://aspargolabs.com
- 16.9.·📈 Technical and fundamental signals in focus The stock shows positive technical signs on the monthly chart: ✅ OBV breaks up – volume precedes price ✅ MACD turns up ✅ PVO strengthens momentum OBV may be a sign that institutional investors have started to position themselves. This may indicate that “smart money” expects a larger move ahead. The price has consolidated – but behind the scenes, things are happening. OBV is based on the principle that “volume precedes price”. This means that volume changes often occur before the price movement itself picks up. Bullish divergence: When the stock price makes lower lows but OBV shows higher lows, it indicates that sellers are losing power – a potential signal that an upward turn is near. Volume spikes: If OBV breaks past resistance while the price is still moving sideways, it may indicate that the price is about to make a breakthrough and may soon start following the upward move. ⸻ 🔬 Fundamental catalysts to watch: • Ovaprene study may be completed before June 2026 (according to new update in September on ClinicalTrials.gov). Potential game-changer in women's health. • Sildenafil for women could generate significant revenue as early as 2026 – difficult to quantify, but the upside is there. Sales are planned to begin in Q4, 2025. • Capital raising recently completed: 4.3M shares sold for $18M. The price was pressured in the short term – but the company is now funded for a year. The subsequent decline in the share price seems mainly linked to this dilution, rather than fundamental deterioration – something that came after the positive Ovaprene news this summer. • In Q4 we will learn which funds bought in at an average of $4.16 – can provide strong signaling value. ⸻ 📊 OBV – why it matters: When OBV breaks up while the price is still – it is often the price that adjusts. Volume = early warning. Bullish divergences + rising volume = momentum is building. The price can be still for months – but when it breaks free, it can move quickly. ⸻ 💡 Summary: The risk level is high – but so is the potential. The combination of certain technical indicators in the monthly chart, potentially new stronger owners and possible catalysts gives reason to keep the stock under surveillance for 2026. The stock's shorting has dropped sharply to about 200k from 1.1M since this summer, but shorts are still active, which is noticeable in that short borrow fee rates are around 10%. The technicals are constructive, especially on the monthly chart, while fundamentals such as the Ovaprene study, potential Sildenafil revenue and potential increased institutional ownership support a more positive long-term view. The short term may remain sluggish, but indicators point to a possible breakout as volume and sentiment converge. My assessment is that the “smart money” has already started to position itself, suggesting that a larger move may be in the offing. If so, there is potential for the price to once again reach levels seen at the peaks of the past five years. For those who are familiar with the company, it becomes clear that there are several potential catalysts ahead. Several analysts’ target prices have recently been updated to an average of $10.33, with a buy recommendation. Today, the stock is trading at $2. My opinion and no advice. I have recently purchased shares. Read up on the company, especially their SEC filings. https://ir.darebioscience.com/financial-information/sec-
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt